1
|
Viana M, Sances G, Ghiotto N, Guaschino E, Allena M, Nappi G, Goadsby PJ, Tassorelli C. Variability of the characteristics of a migraine attack within patients. Cephalalgia 2016; 36:825-30. [DOI: 10.1177/0333102415613612] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 09/26/2015] [Indexed: 01/03/2023]
Abstract
Background Migraine attacks may present different features in different patients and also within the same patient. The percentage of patients reporting stereotyped attacks and those reporting attacks with different phenotypes has not been the object of specific investigations. Objective The objective of this article is to evaluate the percentage of migraine patients reporting the same characteristics, in terms of phenotype and response to symptomatic medications on three consecutive migraine attacks. Methods Thirty patients with migraine without aura prospectively recorded the features of three consecutive attacks in a headache diary. Characteristics recorded were: pain intensity, presence of nausea, vomiting, photophobia, phonophophia, osmophobia, allodynia, cranial autonomic symptoms (at least one), and premonitory symptoms. Patients were allowed to take frovatriptan as symptomatic medication, whose efficacy was evaluated as the two hours pain-free status. Results None of the patients presented identical characteristics on the three studied attacks. This was still the case if we reduced the number of variables evaluated from 11 to seven of the eight core features indicated by the ICHD. Considering just six variables: unilaterality and quality of pain, presence/absence of nausea, vomiting, photophobia and phonophobia, only two patients (6%) had identical features on three consecutive attacks. With respect to the response to frovatriptan, 39% of patients had the same response, either positive (i.e. pain free after two hours) or negative (i.e. not pain free after two hours) on three consecutive attacks. Conclusion Migraine attacks show a high variability not just among patients, but also within the same patient. Our data indicate that stereotypy of attacks is uncommon, and reinforces the underlying logic of the current operational classification system.
Collapse
Affiliation(s)
- M Viana
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - G Sances
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - N Ghiotto
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - E Guaschino
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - M Allena
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - G Nappi
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
| | - PJ Goadsby
- Headache Group – NIHR-Wellcome Trust Clinical Research Facility, King’s College London, UK
| | - C Tassorelli
- Headache Science Center, C. Mondino National Neurological Institute, Pavia, Italy
- Dept. of Brain and Behavioral Sciences, University of Pavia, Italy
| |
Collapse
|
2
|
Viana M, Genazzani AA, Terrazzino S, Nappi G, Goadsby PJ. Triptan nonresponders: do they exist and who are they? Cephalalgia 2013; 33:891-6. [PMID: 23564209 DOI: 10.1177/0333102413480756] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Triptans represent the best treatment option for most migraine attacks, although this is not as well studied as it might be in controlled trials. Their efficacy and tolerability vary, both between agents, and from patient to patient, with about 30%-40% of patients not responding adequately to therapy. As yet unexplained, the failure of one triptan does not predict failure with another, and therefore triptan nonresponders cannot be defined as individuals who have failed a single triptan. Five clinical studies provide evidence that switching from a triptan that is ineffective to a second one can result in effective treatment in a proportion of patients. Systematic studies investigating whether there are patients who do not respond to all triptans in all formulations are lacking. METHODS Here we discuss the importance of identifying triptan nonresponders, the literature supporting their existence, and the issues to be resolved to design trials to investigate this. CONCLUSION So far, no scientific data about the presence of a triptan nonresponder population are available. We propose a pragmatic study design to assess the existence of this subpopulation, recognizing the complexity of the question and the likelihood that more than one issue is at play in nonresponders.
Collapse
Affiliation(s)
- Michele Viana
- Headache Science Center, C. Mondino National Institute of Neurology Foundation, IRCCS, Pavia, Italy.
| | | | | | | | | |
Collapse
|
3
|
Díaz-Insa S, Goadsby PJ, Zanchin G, Fortea J, Falqués M, Vila C. The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study. Int J Neurosci 2011; 121:655-61. [PMID: 21777163 DOI: 10.3109/00207454.2011.605191] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The objective of this study was to evaluate the impact of allodynia on treatment outcomes in the patients with acute migraine treated in the "Act when Mild" (AwM) study. AwM, a randomized placebo-controlled trial, studied almotriptan 12.5 mg in the early treatment (within 1 hr) of acute migraine when the pain was still mild, and investigated clinical outcomes in the presence or absence of allodynia, which was prospectively recorded using patient questionnaires. Of the total population, 39% (n = 404) reported allodynia that did not alter the efficacy of almotriptan administered for early/mild pain in terms of 2-hr pain-free rates (53.9% for allodynic patients vs. 52.5% for nonallodynic patients). Similarly, sustained pain-free rates were 47.2% versus 45.5%, and migraine duration 1.40 versus 1.54 hr, respectively. However, allodynia impaired the effectiveness of almotriptan in the patients with moderate/severe pain in terms of longer migraine duration, fewer patients achieving pain-free status, and more requiring rescue medication. In conclusion, the lack of effect of allodynia on the efficacy of almotriptan given for early/mild migraine pain might help explain the improved outcomes associated with the early-treatment strategy in AwM. Moreover, the data suggest that pain intensity is the main driver of triptan response, and not the presence or absence of allodynia.
Collapse
Affiliation(s)
- S Díaz-Insa
- Headache-Neurology Unit, Hospital Francesc de Borja de Gandia, Spain.
| | | | | | | | | | | |
Collapse
|
4
|
Calatayud-Pascual MA, Balaguer-Fernández C, Serna-Jiménez CE, Del Rio-Sancho S, Femenía-Font A, Merino V, López-Castellano A. Effect of iontophoresis on in vitro transdermal absorption of almotriptan. Int J Pharm 2011; 416:189-94. [PMID: 21736929 DOI: 10.1016/j.ijpharm.2011.06.039] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Revised: 06/21/2011] [Accepted: 06/21/2011] [Indexed: 11/28/2022]
Abstract
The aim of the present work was to characterize the in vitro transdermal absorption of almotriptan through pig ear skin. The passive diffusion of almotriptan malate and its iontophoretic transport were investigated using current densities of 0.25 and 0.50mA/cm(2). In vitro iontophoresis experiments were conducted on diffusion cells with an agar bridge without background electrolytes in the donor compartment. Although both current densities applied produced a statistically significant increment with respect to passive permeation of almotriptan (p<0.01), that of 0.50mA/cm(2) proved to be the best experimental condition for increasing the transport of almotriptan across the skin. Under these experimental conditions, the transdermal flux of the drug increased 411-fold with respect to passive diffusion, reaching 264±24μg/cm(2)h (mean±SD). Based on these results, and taking into account the pharmacokinetics of almotriptan, therapeutic drug plasma levels for the management of migraine could be achieved via transdermal iontophoresis using a reasonably sized (around 7.2cm(2)) patch.
Collapse
|
5
|
Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. J Headache Pain 2011; 12:361-8. [PMID: 21437714 PMCID: PMC3094646 DOI: 10.1007/s10194-011-0325-5] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2010] [Accepted: 02/21/2011] [Indexed: 11/26/2022] Open
Abstract
The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The rates of pain free (30% frovatriptan vs. 32% almotriptan) and pain relief (54% vs. 56%) episodes at 2 h did not significantly differ between treatments. This was the case also at 4 h (pain free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent episodes were significantly (P < 0.05) less frequent under frovatriptan (30% vs. 44%), also for the attacks treated within 30 min. No significant differences were observed in sustained pain free episodes (21% vs. 18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.
Collapse
Affiliation(s)
| | | | - Carlo Lisotto
- Ospedale Civile San Vito al Tagliamento, San Vito al Tagliamento, Italy
| | | | | | | | - Lidia Savi
- Department of Neurology, University of Torino, Turin, Italy
| | - Luigi Alberto Pini
- Inter Department Headache and Drug abuse Center, Modena University, Modena, Italy
| | | | | | - Giorgio Zanchin
- Department of Neurology, University of Padova, Padova, Italy
| | | | - Michel D. Ferrari
- Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Filippo Brighina
- Department of Experimental Medicines and Neurological Sciences (BioNec), University of Palermo, Palermo, Italy
| | - Brigida Fierro
- Department of Experimental Medicines and Neurological Sciences (BioNec), University of Palermo, Via La Loggia 1, 90100 Palermo, Italy
| |
Collapse
|
6
|
Antonaci F, De Cillis I, Cuzzoni MG, Allena M. Almotriptan for the treatment of acute migraine: a review of early intervention trials. Expert Rev Neurother 2010; 10:351-64. [PMID: 20187858 DOI: 10.1586/ern.09.160] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Almotriptan is a serotonin (5-hydroxytryptamine)(1B/1D) receptor agonist (triptan) that has shown consistent efficacy in the acute treatment of migraine with excellent tolerability. It is an effective, well-tolerated and cost-effective triptan, as demonstrated by improvement in rigorous, patient-orientated end points, such as 'sustained pain-free without adverse events'. Results from post hoc analyses, observational studies and well-controlled, prospective clinical trials have shown that significant improvements can be achieved if almotriptan 12.5 mg is administered within an hour of migraine onset, particularly when pain is mild, rather than waiting until pain is moderate-to-severe. Benefits were also achieved with early treatment of moderate-to-severe pain. Time-to-treatment was the best predictor of headache duration, whereas initial headache intensity best predicted most other efficacy outcomes. Early administration of almotriptan 12.5 mg not only produced rapid symptomatic relief, it also improved the patient's quality of life and ability to resume normal daily functioning. Furthermore, the efficacy of almotriptan is not significantly affected by allodynia (purported to reduce the efficacy of triptans). Thus, the excellent efficacy and tolerability profile of almotriptan administered early in a migraine attack indicate that it may be a first-line treatment option in this common, underdiagnosed and undertreated disorder.
Collapse
Affiliation(s)
- Fabio Antonaci
- University Centre for Adaptive Disorders and Headache (UCADH), Section of Pavia, Headache Medicine Centre, Polyclinic of Monza, Via Mondino 2, 27100 Pavia, Italy.
| | | | | | | |
Collapse
|